Field Randomization of Nerinetide (NA-1) Therapy in Early Responders
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 532 participants.
Also called NCT02315443
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 532 participants
- Sponsor
- Registry
-
NCT02315443
-
- Other papers using this trial's data
- Efficacy and safety of intravenous nerinetide initiated by paramedics in the field for acute cerebral ischaemia within 3 h of symptom onset (FRONTIER): a phase 2, multicentre, randomised, double-blind, placebo-controlled study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Canada
- Registry status
- Completed
Technical summary
Registry record NCT02315443. Randomized; quadruple masking; primary purpose treatment. Start 2015-03-26 (actual); primary completion 2023-03-27 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Field Randomization of Nerinetide (NA-1) Therapy in Early Responders
- Acronym
- FRONTIER
- Condition
- Acute Cerebral Ischemia
- Intervention (Drug)
- Nerinetide (NA-1)
- Intervention (Drug)
- Placebo
- Lead sponsor
- NoNO Inc.
- Collaborator
- Brain Canada
- Collaborator
- Djavad Mowafaghian Centre for Brain Health
- Collaborator
- Canadian Stroke Network
- Collaborator
- University of Calgary
- Collaborator
- University of Toronto
- Collaborator
- University of British Columbia
- Collaborator
- Genome British Columbia
Record details
- Record id
cardio:ct-nct02315443- Content hash
f34db4d7d6fd8eeba9954cccb1cc7bc0337e5ea8bf73ed997b38f98558ee52cc